Get the Stockscreener App
1.85
10.12%
0.17
After Hours:
1.81
-0.04
-2.16%
Ovid Therapeutics Inc stock is traded at $1.85, with a volume of 5.46M.
It is up +10.12% in the last 24 hours and up +27.59% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$1.68
Open:
$1.69
24h Volume:
5.46M
Relative Volume:
3.55
Market Cap:
$131.74M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-2.4667
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+12.12%
1M Performance:
+27.59%
6M Performance:
+50.41%
1Y Performance:
+268.23%
1-Day Range:
$1.65
$1.85
1-Week Range:
$1.55
$1.85
52-Week Range:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.85 | 119.64M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Roth Capital | Buy |
| Nov-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
OVID Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
OVID: OV329 and OV4071 advance in CNS disorders, with major clinical data expected within 18 months - TradingView
OVID: Two CNS programs—OV329 for epilepsy and OV4071 for psychosis—advance with pivotal data ahead - TradingView
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
Tax-cover sale as Ovid Therapeutics (OVID) CEO granted 1,435,000 options - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) director awarded 65,000 stock options - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) awards 957,000 stock options to director Jeremy Levin - Stock Titan
Ovid Therapeutics (OVID) director granted 65,000-share option award - Stock Titan
Ovid Therapeutics (OVID) director awarded 65,000 stock options vesting in 2027 - Stock Titan
Ovid Therapeutics (OVID) director awarded 65,000 stock options - Stock Titan
Ovid (NASDAQ: OVID) CBFO gets major equity awards, small tax sale - Stock Titan
Aug Final Week: Does Ovid Therapeutics Inc have declining or rising EPSJuly 2025 Intraday Action & Stepwise Trade Signal Implementation - baoquankhu1.vn
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts - MarketBeat
OVID Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ovid Therapeutics (NASDAQ:OVID) Trading 7.3% HigherShould You Buy? - MarketBeat
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Brain disorder drug developer Ovid lines up three investor talks - Stock Titan
Insider Sell: Is Ovid Therapeutics Inc still a buy after recent gainsTrade Risk Report & Stepwise Trade Execution Plans - baoquankhu1.vn
Aug Spikes: Is Ovid Therapeutics Inc still a buy after recent gainsMarket Activity Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
ADAR1 reports 6.9% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Ovid Therapeutics (OVID) Sees 42.98% Increase Over the Past Week: Key Insights to Consider - Intellectia AI
ZCMD, ABCL, VOR, IXHL, OVID, BFRG Surge in After-Hours Trading Due to Clinical Progress and Recent Developments - Intellectia AI
Is Ovid Therapeutics Inc. being accumulated by smart moneyPortfolio Performance Summary & Daily Profit Focused Stock Screening - mfd.ru
Is Ovid Therapeutics (OVID) one of the best fast growing penny stocks to buy according to analysts? - MSN
Will Ovid Therapeutics Inc. announce a stock splitOptions Play & Safe Entry Point Alerts - mfd.ru
Is Ovid Therapeutics Inc. (1OT) stock a buy for dividend portfolios2025 Price Targets & Verified Swing Trading Watchlists - mfd.ru
What are Ovid Therapeutics Inc.’s earnings expectationsWeekly Trend Report & Low Volatility Stock Suggestions - mfd.ru
What makes Ovid Therapeutics Inc. stock attractive todayJuly 2025 Technicals & Safe Capital Allocation Plans - mfd.ru
IPO Launch: Is Ovid Therapeutics Inc being accumulated by smart moneyJuly 2025 Reactions & Low Drawdown Trading Strategies - baoquankhu1.vn
Aug Retail: Can Silicom Ltd. navigate macro headwindsM&A Rumor & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Rating of “Buy” from Analysts - Defense World
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Risk Hedge: Is Ovid Therapeutics Inc stock risky to hold nowJuly 2025 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Ovid Therapeutics $OVID Position Cut by TLS Advisors LLC - MarketBeat
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? - Finviz
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Both retail investors who control a good portion of Ovid Therapeutics Inc. (NASDAQ:OVID) along with institutions must be dismayed after last week's 11% decrease - simplywall.st
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha
Gains Report: Will Ionis Pharmaceuticals Inc benefit from sector rotation2025 Retail Activity & Growth Focused Investment Plans - baoquankhu1.vn
Does Ovid Therapeutics Inc. have declining or rising EPSWeekly Trend Report & Weekly Stock Breakout Alerts - mfd.ru
Why Ovid Therapeutics Inc. (1OT) stock stays on top picksTrading Volume Trends & Use Time as Your Investing Ally - bollywoodhelpline.com
Investment Recap: Will Ovid Therapeutics Inc announce a stock splitEntry Point & Expert Curated Trade Ideas - baoquankhu1.vn
What is the target price for Ovid Therapeutics Inc. stockQuarterly Trade Summary & Weekly Top Gainers Alerts - bollywoodhelpline.com
Sectors Review: Is Ovid Therapeutics Inc stock risky to hold now2025 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Risk Hedge: Will BMBL benefit from AI trends2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Why is Ovid Therapeutics Inc stock going upEarnings Risk Summary & Low Drawdown Trading Techniques - baoquankhu1.vn
Can Ovid Therapeutics Inc. (1OT) stock sustain breakout momentumJuly 2025 Summary & Fast Exit/Entry Strategy Plans - bollywoodhelpline.com
Ovid Therapeutics (NASDAQ:OVID) Downgraded to Sell Rating by Wall Street Zen - Defense World
Aug Analyst Calls: What risks investors should watch in Ovid Therapeutics Inc stockWeekly Trading Summary & Verified Technical Signals - Bộ Nội Vụ
Market Review: Does Ovid Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
How Ovid Therapeutics Inc. stock performs in weak economyMarket Growth Review & Accurate Entry/Exit Alerts - Улправда
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ovid Therapeutics Inc Stock (OVID) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):